Metamizol Tad

Metamizole Sodium Monohydrate, the active ingredient in Metamizol Tad, is a pyrazolone presented as a parenteral solution for intramuscular and intravenous use. It provides analgesic and antipyretic effects for adults experiencing pain or fever, including postoperative discomfort and visceral colic.

GNH USA supplies Metamizol Tad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows EU‑quality standards and offers reliable global distribution.

Metamizole is employed to manage pain and fever across several clinical settings.

Pain: provides relief of moderate to severe acute pain Fever: reduces elevated body temperature in febrile patients Postoperative pain: controls pain following surgical procedures Colic: alleviates visceral pain associated with intestinal colic

Metamizole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hypotension: transient drop in blood pressure after injection - Nausea: mild to moderate feeling of queasiness - Vomiting: occasional emesis following administration - Injection site reactions: pain, redness or swelling at the site

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells - Anaphylaxis: life‑threatening allergic reaction - Stevens‑Johnson syndrome: severe skin and mucous membrane disorder - Hepatic dysfunction: abnormal liver enzyme elevations

Before using Metamizol Tad, consider the following precautions.

Assess renal function: adjust use in patients with renal impairment Monitor blood counts: watch for signs of agranulocytosis Use cautiously in hepatic disease: avoid in severe liver dysfunction Avoid in known hypersensitivity: discontinue if allergic reaction occurs Do not combine with other myelosuppressive agents: increased risk of blood disorders Store at ambient temperature: keep in original packaging, protect from moisture and light

Metamizol Tad can interact with several drug classes; awareness of these interactions helps minimize risk.

Major Interactions (Avoid): - Concurrent myelosuppressive drugs: may amplify risk of agranulocytosis - Other NSAIDs: increase gastrointestinal bleeding potential - Drugs causing agranulocytosis (e.g., carbamazepine): heightened hematologic risk - Anticoagulants: may enhance bleeding tendency

Moderate Interactions (Monitor Closely): - Antihypertensives: additive hypotensive effect - Diuretics: possible electrolyte disturbances - CYP‑metabolized drugs: may alter plasma concentrations of co‑administered agents